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Abstract
In this commentary, we summarize the most recent advances in the cytokine-targeting therapies.
We focus on new aspects of interleukin-1 (IL-1)-mediated autoinflammation and novel strategies to
target IL-1.
Introduction and context
The treatment of the broad and heterogeneous group
of inflammatory diseases has been revolutionized with
the introduction of therapies that target cytokines [1].
Since 1998, the year that tumor necrosis factor-alpha
(TNF-a) blockade was first approved for rheumatoid
arthritis (RA), our cytokine-targeting armamentarium
has been enriched [1]. Table 1 summarizes all of the
anti-cytokine regimens approved by the US Food and
Drug Administration (FDA), and Table 2 lists the
cytokine-targeting therapies that are still under inves-
tigation [2]. Recent evidence suggests that interleukin-6
(IL-6) blockade using tocilizumab is effective in RA [3]
and that the p40 neutralizing antibody ustekinumab
(targeting both IL-12 and IL-23) is beneficial for
psoriasis [4].
Despite all of these breakthroughs in targeting cyto-
kines, the treatment of inflammatory diseases is still
imperfect and challenging. The high cost and the
treatment-related adverse events (mainly infections
and the reported, but controversial, increased risk for
malignancies) are major drawbacks of cytokine target-
ing [5-7]. In addition, the available cytokine blockade is
not always effective, as exemplified by the failure of the
anti-p40 monoclonal antibody to show a significant
benefit in patients with multiple sclerosis [8]. Further-
more, approximately 30% of RA patients do not
respond adequately to anti-TNF-a treatments [9] and
the IL-1 inhibitor anakinra appears to be only moder-
ately effective in its FDA-approved indication for RA in
clinical practice [5].
Although anakinra did not fulfill all of the expectations
for managing RA, this therapeutic showed remarkable
effectiveness in a heterogeneous group of heritable and
sporadic disorders now considered IL-1-mediated
autoinflammatory diseases [10]. The prototype of
these diseases is the cryopyrin-associated periodic
syndrome (CAPS) [11]. CAPS is now considered a
continuum of one disorder with varying severity and
includes the mild phenotype known as familial cold
autoinflammatory syndrome (FCAS), the intermediate
Muckle-Wells syndrome (MWS), and the severe form
of neonatal-onset multisystem inflammatory disorder
(also called chronic infantile neurologic cutaneous and
articular syndrome) [11].
The immune system discriminates self from nonself and
distinguishes pathogens from commensal organisms and
specifically eliminates pathogens. Regulation of immune
responses restrains concurrent tissue damage and
orchestrates tissue repair. This balance between defense
and protection of tissue integrity results from a tight
regulation of the innate and adaptive branches of
the immune system. Failure of these regulatory mecha-
nisms causes an aberrant immune response ranging
from inadequate defense to uncontrolled/unprovoked
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or autoreactive T-cell clones or both, due to deregulated
adaptive immunity, leads to ‘autoimmunity’ [12].
Systemic lupus erythematosus exemplifies systemic
autoimmunity, whereas autoimmune thyroiditis and
diabetes mellitus type I reflect some facets of tissue-
specific autoimmunity [12].
Now it is well established that genetic defects in
molecules regulating the function of the innate immune
system are the cause of several diseases characterized by
systemic or localized inflammation in the absence of
infection, autoreactive lymphocytes, and high titers
of autoantibodies [11,13,14]. To distinguish this group
of diseases from autoimmune diseases, emphasizing the
primary role of innate immunity in driving their
pathogenesis, the term ‘autoinflammatory diseases’ has
been proposed [11,13,14]. The new aspects in the
concept of IL-1-mediated autoinflammation and the
recent advances in targeting IL-1 will be the focus of this
commentary.
Major recent advances
Understanding Horror autoinflammaticus
Morethan60mutationsintheCIAS1geneareresponsible
forahyperactive NALP3(cryopyrin)leadingtoCAPS[11].
NALP3 functions as a sensor of pathogens and danger
signals and is expressed mainly in immune cells,
chondrocytes, and epithelial cells [15]. Upon activation,
NALP3 recruits ASC (apoptosis-associated speck-like
protein containing caspase-recruitment domain), Cardi-
nal, and pro-caspase-1, assembling a multimeric complex
called the inflammasome. NALP3 inflammasomes acti-
vate the downstream caspase-1, the protease that cleaves
pro-IL-1, releasing the potent pyrogen IL-1b [15,16]. The
understanding of the direct role of NALP3 in IL-1b
processing led to the concept that CAPS (a result of
hyperactive inflammasome due to mutated NALP3) is an
IL-1-mediated autoinflammatory disease, justifying the
use of IL-1 blockade to control disease activity [11].
Targeting IL-1b to treat autoinflammation
The recombinant human IL-1 receptor antagonist ana-
kinra was the first IL-1-targeting intervention used in
patients with CAPS with impressive effectiveness
[17-19]. The short half-life of anakinra necessitates
daily injections for efficient responses, and injection
site reactions are commonly observed [5,17-19]. To
overcome these limitations, sophisticated investigation
resulted in new efficient strategies to target IL-1 with
improved pharmacokinetics and thus better compliance
and tolerance [20,21].
Rilonacept is a new IL-1 blocker that functions as an
IL-1 trap, binding IL-1 with an affinity at least 100-fold
higher than that of the native IL-1 cell surface receptor
complex [22]. Normally, IL-1b binds first to IL-1RI on
the surface of target cells and subsequently IL-1
accessory protein (IL-1AcP) is recruited, thus forming
a trimolecular signaling complex [16]. Rilonacept is an
artificial molecule that contains the ligand-binding
portions of both IL-1RI and IL-1AcP fused to a dimeric
molecule containing the Fc segment of hIgG1 (human
immunoglobulin G1) [22]. In contrast to the
daily injected anakinra, rilonacept has a half-life of
approximately 7 days and thus is administered once
weekly [20].
Table 1. Cytokine-targeting therapies approved by the US Food
and Drug Administration for the treatment of inflammatory
diseases
Targeted cytokine Description FDA-approved
indications
TNF-a
1. Etanercept (Enbrel
®;
Amgen, Thousand Oaks,
CA, USA, and Wyeth,
Madison, NJ, USA)
Dimeric fusion protein
consisting of the
ligand-binding portion of
human p75TNFR linked
to the Fc of human IgG1
￿ RA
￿ JIA
￿ ASp
￿ Psoriasis
￿ PsA
2. Infliximab
(Remicade
®; Johnson &
Johnson, New
Brunswick, NJ, USA)
Chimeric (human and
mouse) IgG1k
anti-TNF-a Mab
￿ RA
￿ ASp
￿ Psoriasis
￿ PsA
￿ CD
￿ UC
3. Adalimumab
(Humira
®; Abbott
Laboratories, Abbott
Park, IL, USA)
Recombinant human IgG1
anti-TNF-a Mab
￿ RA
￿ JIA
￿ ASp
￿ Psoriasis
￿ PsA
￿ CD
4. Certolizumab pegol
(Cimzia
®; UCB,
Brussels, Beglium)
Humanized Fab fragment
of anti-TNF-a Mab
conjugated to PEG
￿ RA
￿ CD
5. Golimumab
(Simponi™; Centocor
Ortho Biotech, Inc.,
Horsham, PA, USA)
Human IgG1k
anti-TNF-a Mab
￿ RA
￿ ASp
￿ PsA
IL-1
1. Anakinra (Kineret
®;
Amgen)
Recombinant human
IL-1Ra that inhibits IL-1 by
binding IL-1RI
￿ RA
2. Rilonacept
(Arcalyst™; Regeneron
Pharmaceuticals, Inc,
Tarrytown, NY, USA)
Consisting of the
ligand-binding domains of
human IL-1RI and IL-1AcP
fused in line with Fc of
human IgG1 (IL-1 trap)
￿ CAPS
ASp, ankylosing spondylitis; CAPS, cryopyrin-associated periodic
syndrome; CD, Crohns disease; Fab, fragment antigen-binding; FDA, US
Food and Drug Administration; IgG, immunoglobulin G; IL-1, interleukin-1;
IL-1AcP, interleukin-1 accessory protein; IL-1Ra, interleukin-1 receptor
antagonist; JIA, juvenile idiopathic arthritis; Mab, monoclonal antibody;
PEG, polyethylene glycol; PsA, psoriatic arthritis; RA, rheumatoid arthritis;
TNF-a, tumor necrosis factor-alpha; TNFR, tumor necrosis factor
receptor; UC, ulcerative colitis.
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'In February 2008, rilonacept (Arcalyst™; Regeneron
Pharmaceuticals, Inc, Tarrytown, NY, USA) was approved
by the FDA for the treatment of CAPS. IL-1 trap was
proven very effective and safe in a small open-label pilot
study [23] and in a larger two-part phase III clinical trial
[24] which included patients with FCAS and MWS.
Rilonacept not only rapidly improved patients’ symp-
toms, but also reduced serum levels of serum amyloid A
(SAA) [20,24]. The latter is of great importance given that
high serum levels of SAA are directly related to the risk of
developing secondary amyloidosis [25], the main cause of
renal insufficiency in these patients. Injection site
reactions and upper respiratory tract infections were the
two most commonly observed adverse events in patients
treated with rilonacept [20].
A third IL-1 blocker, the monoclonal human anti-IL-1b
canakinumab (ACZ885), was used in patients with
CAPS in one small study [26] and a second recently
reported randomized placebo-control clinical trial [27].
Canakinumab was administered subcutaneously once
every 8 weeks and induced a remarkable clinical
response with normalization of SAA and C-reactive
protein levels [27]. During the treatment period, only
two serious adverse events were observed: one case of
urosepsis and an episode of vertigo [27].
Table 2. Cytokine-targeting therapies that are under investigation in clinical trials
Targeted cytokine Description Investigational trials
IL-1
Rilonacept IL-1 trap (Table 1) FMF/AOSD/SoJIA/Gout
Canakinumab Anti-IL-1 Mab CAPS/SoJIA/RA/Gout/DM II/COPD
IL-4 and IL-13
Pascolizumab Anti-IL-4 Mab Asthma
Pitrakinra (blocks IL-4 and IL-13) Mutated IL-4 Asthma
CAT-354, IMA-638, QAX576 Anti-IL-13 Mabs Asthma/IPF/Allergic rhinitis/SSc
IL-5
Mepolizumab Anti-IL-5 Mab Asthma/CSS/HES
MEDI-563 Anti-IL-5R Mab Asthma
IL-6
Tocilizumab Anti-IL-6R Mab RA/SoJIA
IL-9
MEDI-528 Anti-IL-9 Mab Asthma
p40 (IL-12 and IL-23)
Ustekinumab (CNTO 1275) hIgG1 anti-p40 Mab Psoriasis/PsA/CD
ABT-874/J695 hIgG1l anti-p40 Mab Psoriasis/CD
IL-15
HuMax-IL-15 (AMG 714) Anti-IL-15 Mab RA/Psoriasis
IL-17A
AIN457 Anti-IL-17A Mab RA/Psoriasis/PsA/ASp/CD/Uveitis
IL-23
Anti-p19 Mab Clinical trials in preliminary stage. No further
information available.
TGF-b
CAT-192 Anti-TGF-beta1 Mab SSc
TNF superfamily
1. BAFF(BLyS)/APRIL
Atacicept (blocks BLyS and APRIL) Ligand-binding portion of TACI fused with hIgG1 Fc SLE/RA/MS/Optic neuritis
Belimumab Anti-BLyS Mab SLE/RA
2. LTa1b2 and LIGHT
Baminercept Ligand-binding portion of LT-b R fused with hIgG1 Fc RA
3. RANKL
Denosumab Anti-RANKL Mab RA
IFN-a
MEDI-545 Anti-IFN-a Mab SLE/Psoriasis
For further information, see [2]. AOSD, adult-onset Still’s disease; APRIL, a proliferation-inducing ligand; ASp, ankylosing spondylitis; BAFF, B-cell
COPD, chronic obstructive pulmonary disease; CSS, Churg-Strauss syndrome; DM II, diabetes mellitus type II; FMF, familial Mediterranean fever;
HES, hyper-eosinophilic syndromes; hIgG1, human immunoglobulin G1; IFN-a, interferon-alpha; IL, interleukin; IPF, idiopathic pulmonary
fibrosis; LIGHT, lymphotoxin-related inducible ligand that competes for glycoprotein D binding to herpesvirus entry mediator on T cells; LT,
lymphotoxin; Mab, monoclonal antibody; MS, multiple sclerosis; PsA, psoriatic arthritis; RA, rheumatoid arthritis; RANKL, receptor activator of nuclear
factor-kappa B ligand; SLE, systemic lupus erythematosus; SoJIA, systemic onset juvenile idiopathic arthritis; SSc, systemic scleroderma; TACI,
transmembrane activator and CAML (calcium modulator and cyclophilin ligand) interactor; TGF-b, transforming growth factor-beta; TNF-a,t u m o r
necrosis factor-alpha.
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' activating factor of tumor necrosis factor family; BLyS, B lymphocyte stimulator; CAPS, cryopyrin-associated periodic syndrome; CD, Crohns disease;Future directions
Recently, it was shown that MSU (monosodium urate
monohydrate) and CPPD (calcium pyrophosphate
dihydrate) crystals activate NALP3 inflammasome and
that IL-1 plays a central role in driving acute inflamma-
tion during gout and pseudo-gout attacks [28]. In a small
uncontrolled study and in case reports, anakinra has
been proven to be very effective in controlling disease
flares in patients with gout and pseudo-gout [29-31].
Rilonacept and canakinumab are under investigation in
crystal-induced arthritides, and the preliminary results
have been promising (Table 2 and [2]). In this context,
targeting IL-1 could be a therapeutic alternative, at least
for the cases of crystal-induced arthritis with refractori-
ness or intolerance to the standard treatment with
nonsteroidal anti-inflammatory drugs, steroids, and
colchicine.
The group of IL-1-mediated autoinflammatory diseases
has been broadened with the addition of TNF receptor-
associated periodic syndrome, familial Mediterranean
fever, hyper-IgD syndrome, PAPA (pyogenic arthritis,
pyoderma gangrenosum, and acne) syndrome, Schnit-
zler syndrome, systemic onset juvenile idiopathic arthri-
tis, and adult-onset Still’s disease [11,16]. In the above
inflammatory disorders, anakinra was remarkably effec-
tive [10] and, in the near future, it is expected that the
novel IL-1-targeting therapeutics rilonacept and canaki-
numab will be useful treatment choices for these
diseases.
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